1,482 results on '"MORABITO, FORTUNATO"'
Search Results
2. Outcomes Before and After Implementation of the ERAS (Enhanced Recovery After Surgery) Protocol in Open and Laparoscopic Colorectal Surgery: A Comparative Real-World Study from Northern Italy
3. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia
4. Momelotinib in myelofibrosis
5. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
6. Characteristics and Outcomes of Colorectal Cancer Patients Cared for by the Multidisciplinary Team in the Reggio Emilia Province, Italy.
7. Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern Italy.
8. Selinexor in multiple myeloma
9. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
10. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies
11. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort
12. A Case Report on Diagnostic, Genetic and Therapeutic Challenges in Mixed Phenotype Acute Leukemia
13. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
14. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
15. Optimizing Outcomes through a Multidisciplinary Team Approach in Endometrial Cancer
16. Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors
17. Ivosidenib in acute myeloid leukemia
18. Teclistamab‐cqyv in multiple myeloma
19. Tagraxofusp in myeloid malignancies
20. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
21. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
22. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
23. Teclistamab‐cqyv in multiple myeloma.
24. Optimizing Outcomes through a Multidisciplinary Team Approach in Endometrial Cancer.
25. Tagraxofusp in myeloid malignancies.
26. Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
27. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
28. Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020
29. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials
30. Glasdegib for the treatment of acute myeloid leukemia
31. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
32. Zanubrutinib for the treatment of chronic lymphocytic leukemia
33. Belantamab mafodotin in multiple myeloma
34. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
35. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model
36. Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study
37. Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia
38. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
39. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
40. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
41. Myelodysplastic syndromes with ring sideroblasts.
42. A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI)
43. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
44. Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
45. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
46. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
47. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
48. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
49. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
50. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.